Among that, melanoma patients with low PARP4 expression (N = 234) were more sensitive to the ATM inhibitor KU55933 (Wilcoxon rank sum test, P = 0.043), but not to other inhibitors like ATR inhibitor (Wilcoxon rank sum test, dactolisib, P = 0.935; ceralasertib, P = 0.479; berzosertib, P = 0.57), or PARP inhibitor (Wilcoxon rank sum test, talazoparib, P = 0.336). Here, ATM is linked to melanoma.